The convergence of two already fantastic industries is creating an incredible opportunity.

Alphabet may be moving in the wrong direction this year, at least so far, but the company's multiple growth avenues (even ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.11, moving +1.63% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.11%.

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Chief Financial Officer Ben Taylor outlined the company’s integrated approach to AI-enabled drug discovery and development, ...

In March 2026, Citeline announced an expanded strategic partnership with Recursion Pharmaceuticals to integrate Citeline's real-world data and evidence into Recursion’s tech-enabled drug discovery and ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is set to give its latest quarterly earnings report on Wednesday, 2026-02-25. Here's what investors need to know before the announcement. Analysts estimate that ...